The objective of this study is to investigate the safety and efficacy of administering 372.6 mg of AK1820 (isavuconazonium sulfate) intravenously or orally to adult Japanese patients with deep mycosis. The primary endpoint is safety (percentage of patients with adverse events after starting the study treatment).
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Percentage of patients with adverse events between the first administration of investigational product and the end of Follow-up.
Timeframe: From the first study drug administration until 28 days after the last dose of study drug (up to approximately Day 112).